HALO
$57.16
Revenue | $264.86Mn |
Net Profits | $118.1Mn |
Net Profit Margins | 44.59% |
PE Ratio | 14.85 |
Halozyme Therapeutics, Inc.’s revenue jumped 35.22% since last year same period to $264.86Mn in the Q1 2025. On a quarterly growth basis, Halozyme Therapeutics, Inc. has generated -11.12% fall in its revenue since last 3-months.
Halozyme Therapeutics, Inc.’s net profit jumped 53.72% since last year same period to $118.1Mn in the Q1 2025. On a quarterly growth basis, Halozyme Therapeutics, Inc. has generated -13.81% fall in its net profits since last 3-months.
Halozyme Therapeutics, Inc.’s net profit margin jumped 13.69% since last year same period to 44.59% in the Q1 2025. On a quarterly growth basis, Halozyme Therapeutics, Inc. has generated -3.02% fall in its net profit margins since last 3-months.
Halozyme Therapeutics, Inc.’s price-to-earnings ratio after this Q1 2025 earnings stands at 14.85.
EPS Estimate Current Quarter | 1.43 |
EPS Estimate Current Year | 1.43 |
Halozyme Therapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at 1.43 - a 18.18% jump from last quarter’s estimates.
Halozyme Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at 1.43.
Earning Per Share (EPS) | 0 |
Halozyme Therapeutics, Inc.’s earning per share (EPS) fell -100% since last year same period to 0 in the Q2 2025. This indicates that the Halozyme Therapeutics, Inc. has generated -100% annual rate of fall in its earning per share (EPS) in the last 4 quarters.
Earnings Date | Estimated EPS | Reported EPS | Surprise % |
---|---|---|---|
2025-08-12 | 1.21 | 0 | -100% |
2025-05-06 | 0.97 | 1.11 | 14.2% |